Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on ARCT stock, giving a Buy rating on October 1.

CSL Limited (OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) announced the results of a Phase 3 head-to-head study of ARCT ...

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of ...

Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months. The table below summarizes ...

A total solar eclipse in April. Beautiful northern lights in May. Now, October is giving Ohioans a chance to see possibly the ...

On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...

On Wednesday, H.C. Wainwright maintained a positive outlook on Arcturus Therapeutics (NASDAQ:ARCT), reiterating a Buy rating and a $63.00 price target for the stock. The firm's stance comes after ...

Corona Borealis, "The Northern Crown,” is one of those rare constellations that actually looks like what it represents. It is ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...